Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 3/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.33 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.33 |
| ▸ | VNN1 | O95497 | 3/20 | 0.32 |
| ▸ | BTD | P43251 | 1/20 | 0.32 |
| ▸ | PDE9A | O76083 | 3/20 | 0.32 |
| ▸ | HPGD | P15428 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5015298 | 0.81 | PRMT3 (0.35) | PIK3CDIRAK4PRMT3VNN1BTD | |
| SCHEMBL5013993 | 0.74 | P4HB (0.34) | IRAK4PRMT3 | |
| SCHEMBL5032126 | 0.69 | P4HB (0.35) | IRAK4 | |
| SCHEMBL1567451 | 0.68 | HPGD (0.34) | IRAK4PRMT3VNN1BTDHPGD | |
| SCHEMBL12370932 | 0.68 | PIK3CD (0.43) | PIK3CDIRAK4 | |
| SCHEMBL17770563 | 0.68 | PRMT3 (0.35) | PRMT3VNN1BTDHPGD | |
| SCHEMBL17770565 | 0.68 | PRMT3 (0.35) | PRMT3VNN1BTDHPGD | |
| SCHEMBL5014884 | 0.68 | SIGMAR1 (0.38) | — | |
| SCHEMBL1356971 | 0.66 | HDAC8 (0.38) | ALDH1A1 | |
| SCHEMBL5015617 | 0.66 | SIGMAR1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080234262-A1 | PYRAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | WYETH (US) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234262-A1 | PYRAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | MTOR, PIK3CA, PDPK1 | PIK3CD 7/4885IRAK4 239/4885PRMT3 1433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.